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Abstract
Background: The aim was to describe the population of patients with moderate rheumatoid arthritis (RA) in the
United Kingdom and the burden of disease from the perspectives of the patient, caregiver, and health service.
Methods: In this descriptive study, retrospective patient-level data were extracted from hospital medical records to
assess healthcare resource utilisation and validated outcome measures were administered via questionnaire to
patients with moderate RA (Disease Activity Score [DAS28] between 3.2 and 5.1) from eight secondary care centres,
and their caregivers. Patient-reported outcome instruments were scored according to licensed manuals.
Results: Outcome measures were completed by 102 patients and 38 caregivers. The mean EuroQoL-5 dimension-5
level crosswalk index value for patients was 0.62 (SD 0.24) compared to an England population norm of 0.82. Mean
pain VAS score was 37.7 (SD 24.0) and mean Health Assessment Questionnaire Disability Index was 1.1 (SD 0.8). In
employed patients who completed the Work Productivity and Activity Impairment questionnaire (n = 26), a mean
29% (SD 26%) reduction in work productivity was recorded. Patients experienced significant fatigue as a result of
their RA (median Functional Assessment of Chronic Illness Therapy fatigue score 17.2 of a possible 52, interquartile
range [IQR] 11.0–28.8). Over 50% of caregivers reported providing > 7 h of support care per week to the patient
with RA, and 16 and 11% took paid/unpaid leave or reduced working hours, respectively. Mean Caregiver Reaction
Assessment subscale scores were 1.9 (SD 0.9) for finance, 1.7 (SD 0.8) for health, 2.3 (SD 1.0) for schedule disruption,
and 1.9 (SD 0.8) for family support. Patients had a mean 5.5 (SD 4.1) outpatient attendances and a median 9.0 (IQR
2.0–20.0) diagnostic and monitoring tests in the 12 months prior to enrolment.
Conclusions: This study shows that moderate RA has a considerable impact on healthcare resources and on
patients’ and caregivers’ lives. There is scope to improve the management of patients with moderate RA.
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Background
Rheumatoid arthritis (RA) is an autoimmune disorder
that affects more than 400,000 adults (approximately
1%) in the United Kingdom (UK) [1]. Chronic inflamma-
tion results in pain, stiffness, and swelling in the joints,
which over time can lead to cartilage damage and joint
destruction [2–4].
RA is associated with physical and psychological dis-
abilities and poor quality of life and poses a substantial
burden on patients and healthcare resources [5, 6]. De-
pression occurs in 13–42% of patients with RA [7], while
the prevalence of fatigue in RA ranges from 40 to 90%
[8, 9]. RA has a significant impact on work productivity
with important socio-economic consequences [10, 11].
One study showed that 36–84% of individuals with RA
take sickness absence due to their condition, and up to
50% stop work altogether over a period of 4.5–22 years
despite wanting to remain in employment [12]. In the
UK, 10% of early RA patients left work over a median of
3 years of follow-up [13]. Increasing disease severity has
been associated with worsening disability, pain, fatigue,
quality of life, and work and activity impairment [14].
The total (direct and indirect) cost of RA to the UK
economy has been estimated at between £3.8 and £4.8
billion (US$5.1–6.4 billion) [1, 2], while the annual bur-
den of RA across Europe is estimated to be approxi-
mately €3–5000 per patient (US$3589-5982) in non-
drug costs [15].
The National Institute for Health and Care Excellence
(NICE) recommends first-line treatment with conven-
tional disease-modifying antirheumatic drug (cDMARD)
monotherapy using oral methotrexate, leflunomide, or
sulfasalazine. Additional cDMARDs are recommended as
combination therapy when the treatment target (remission
or low disease activity [LDA]) has not been achieved des-
pite dose escalation. Short-term bridging treatment with
glucocorticoids should be considered when a new
cDMARD is started [16]. Biologic (bDMARDs) and tar-
geted synthetic DMARDs are only recommended in the
UK following an inadequate response to a combination of
cDMARDs in patients with severe RA (Disease Activity
Score [DAS28] > 5.1) [16]. This recommendation is more
restrictive than European guidelines, which advise starting
bDMARDs after a first cDMARD strategy has failed [17].
The strict prescription and reimbursement rules in the
UK results in low bDMARD use, which is lower than
countries with comparable Gross Domestic Product per
capita (France, Japan) [18].
The European League Against Rheumatism (EULAR),
as well as NICE, endorse the ‘treat-to-target’ principle
for RA and recommends that the primary treatment goal
in RA should be clinical remission (i.e. absence of signs
and symptoms of significant inflammatory disease activ-
ity) or LDA in order to maximise long-term health-
related quality of life (HRQoL) [16, 17]. Studies have
demonstrated that patients with moderate RA on
bDMARDs are more likely to achieve remission or LDA
than patients with severe RA [19], leading to significant
cost savings in terms of medical visits, laboratory tests,
drug costs, hospitalisation, and days lost from work [20–
22]. However, this is difficult to achieve in UK patients
with an inadequate repsonse to cDMARDs and a
DAS28 < 5.1, as access to bDMARDs is restricted.
There is a paucity of evidence from the UK on burden
of disease in patients who are not eligible for advanced
therapies based on current access restrictions (hereafter
referred to as those with moderate RA disease activity).
This information is important to help understand unmet
needs in this population and to guide future clinical
management. Thus, we aimed to describe this popula-
tion of patients with moderate RA in the UK and the
burden of disease from the perspectives of the patient,
caregiver, and health service.
Methods
Study design
A multi-centre study was conducted at eight secondary
care centres in the UK, including seven in England and
one in Scotland. The study comprised a series of cross-
sectional patient-reported outcome (PRO) question-
naires and matched caregiver questionnaires and a retro-
spective review of patient-level data from hospital
medical records.
Patient and caregiver recruitment
Eligible patients were identified either prospectively (se-
lected consecutively at a routine clinic visit) or retro-
spectively (via the participating site’s clinical database, in
reverse chronological order based on the date of their
most recent DAS28 score) by members of the direct care
team between June 2018 and March 2019. Patients who
met the following criteria were included in the study:
≥18 years of age with a DAS28 score between 3.2 and
5.1 at the time of study enrolment (or at the most recent
recording up to 8 weeks prior to enrolment), confirmed
diagnosis of RA at least 2 years prior to enrolment, and
who received a cDMARD in the 24 months prior to en-
rolment. For the purposes of this study, moderate RA
was defined as a DAS28 > 3.2 ≤ 5.1. The exclusion cri-
teria included DAS28 score > 5.1 recorded at any point
during the 12months prior to enrolment, previous bio-
logic therapy or Janus kinase inhibitor for any condition,
current or previous participation (≤5 years) in an inter-
ventional clinical trial for RA, patient under the care of
the rheumatology department at the participating centre
for less than 12months prior to enrolment, and/or un-
able or unwilling to give consent for study participation.
A sample size of 100 patients was deemed sufficient to
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enable the estimation of endpoints with adequate preci-
sion and also pragmatic based on the number of eligible
patients expected for the study to give a representative
sample of patients with moderate RA.
Caregivers were included if they were aged ≥18 years,
met the definition of an informal caregiver (a spouse,
adult child, other relative, partner, neighbour or friend
who has a personal relationship with and provides a
broad range of unpaid assistance to an adult with RA) at
the time of study enrolment, and were the patient’s pri-
mary caregiver (defined as the person who provides the
most unpaid assistance to the patient for their RA).
Caregivers themselves unable or unwilling to give con-
sent for completion of study questionnaires or those
who cared for patients unable or unwilling to give con-
sent were excluded from the study.
Data collection
Data extracted from hospital medical records included pa-
tient demographics and clinical characteristics, disease se-
verity, comorbidities, disease and treatment history, and
data on healthcare resource utilisation (HCRU) for a mini-
mum of 12months and up to 24months prior to study
enrolment (where data were available). The date of RA
diagnosis and number of cDMARDs received may have
preceded this time period but were still captured in this
study even if the date of diagnosis was more than 24
months prior to enrolment. Source data verification
(SDV) was performed on a 15% random sample of pa-
tients across all participating centres to ensure data
accuracy.
Questionnaires were either administered to the patient
at their routine clinic visit or by post. Validated ques-
tionnaires comprised the following: 5-dimensional Euro-
QoL (EQ-5D-5L), Health Assessment Questionnaire
Disability Index (HAQ-DI), Pain Visual Analogue Scale
(VAS), Functional Assessment of Chronic Illness Ther-
apy - Fatigue (FACIT-F), Morning Joint Stiffness Scale
(MJS), and Work Productivity and Activity Impairment
(WPAI) questionnaire.
These questionnaires have been shown to have excel-
lent psychometric properties, including validity and reli-
ability, for use in RA [23–27].
The EQ-5D-5L measures HRQoL (index score ranges
from worse than dead [< 0] to full health [1]) and com-
prises the following five dimensions: mobility, self-care,
usual activities, pain/ discomfort, and anxiety/depression
[28]. In addition, a VAS is used to assess patient’s self-
rated health status from ‘the worst health you can im-
agine’ (score 0) to ‘the best health you can imagine’
(score 100) with a one-day recall period. The HAQ-DI
was used to assess functional ability and is composed of
20 items belonging to eight categories (dressing and
grooming, getting up, eating, walking, hygiene, reach,
grip, and daily activities) [29]. Scores of 0 to 1 are gener-
ally considered to represent mild to moderate disability,
1 to 2 represent moderate to severe disability, and 2 to 3
represent severe to very severe disability. The Pain VAS
(0 indicates ‘no pain’ and 100 indicates ‘worst pain im-
aginable’) was used to measure the level of pain in the
previous 24 h [30]. The 40-item FACIT-F comprises five
subscales including physical (score range 0–28), social/
family (0–28), emotional (0–24), and functional well-
being (0–28), and the symptom-specific subscale for fa-
tigue (0–52) [31, 32]. The total FACIT-F score ranges
from 0 to 160, and higher scores represent better well-
being for all scales/subscales. The MJS scale comprises
two single-item measures that assess the length of time
(in hours and minutes) and severity (0 indicates ‘no joint
stiffness’ and 10 indicates ‘joint stiffness as bad as you
can imagine’) of morning joint stiffness that patients ex-
perienced on the day of questionnaire completion [23].
The WPAI comprises six sections which are combined
into four domains, including absenteeism, presenteeism,
work productivity loss, and activity impairment [33].
Higher percentages show increased impairment. In
addition to the validated questionnaires, patients were
also asked about any change in employment status as a
result of their RA and activities of daily living they re-
quire support with.
Caregivers were also asked to complete the EQ-5D-5L
to assess the impact of providing care on caregiver
HRQoL and the caregiver-specific WPAI to assess the
impact looking after the RA patient had on caregiver
work productivity. In addition, the validated Caregiver
Reaction Assessment (CRA), which comprises five sub-
scales (impact on schedule, health, finances, caregiver es-
teem, and family support), was used to assess the impact
of caring on the caregiver [34]. The total and five sub-
scale scores range from 1 to 5, where higher scores indi-
cate more substantial impact of providing support.
Caregivers were also asked about the number of hours
of support provided to the patient, the activities of daily
living that the patient requires support with, and
changes in caregiver employment as a result of providing
care to the patient with RA. A Patient Advisory Group
reviewed the patient and caregiver questionnaires.
Statistical analyses
Statistical analyses were performed using Stata version
14.2 (StataCorp, College Station, TX). Initial data pro-
cessing tasks (e.g. quality checks and validations) and
tabulation of results were conducted in Microsoft Excel.
All analyses were performed with the available data with
missing data reported. Quantitative variables approxi-
mating a normal distribution and variables describing
hospital resource utilisation are presented as mean
(standard deviation [SD]); other quantitative variables
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are presented as medians (interquartile range [IQR]).
Categorical variables are described with frequencies and
percentages. Distributions are presented as appropriate
to the variable reported. The cost of HCRU was calcu-
lated using National Health Service (NHS) national
schedule of reference costs (2017/18) [35]. The lowest
cost of each drug referenced in the British National For-
mulary was used for analysis of medication costs [36].
Validated PRO instruments were scored according to li-
censed manuals, and missing data were handled in ac-
cordance with developer’s recommendations.
Results
Study population
A total of 114 patients were included in the analyses. A
flow diagram of patient selection is presented in Fig. 1.
The mean age of included patients was 55.5 (SD 13.9)
years and 75% (85/114) were female (Table 1). The me-
dian disease duration was 7.8 (IQR 3.8–13.6) years at
study enrolment (n = 108) and 5.1 (IQR 2.3–10.9) years at
current cDMARD initiation (n = 102). All patients had a
DAS28 score between 3.2 and 5.1 at their visit closest to
enrolment (mean 3.8 [SD 0.5]) indicating moderate dis-
ease activity at the time of recruitment. Only 10% (7/70)
and 17% (12/70) of DAS28 scores in the 12months prior
to enrolment indicated remission or LDA, respectively;
73% (51/70) indicated moderate disease. Patients had
more tender joints (median 3.0 [IQR 2.0 to 5.0]) than
swollen joints (median 1.0 [IQR 1.0 to 3.0]). Patients had a
median of 2.0 (IQR 1.0 to 2.0) comorbidities at enrolment;
15% (n = 17) had no comorbidities. The most common
comorbidity was cardiovascular disease (n = 33, 29%),
followed by respiratory disease (n = 28, 25%), osteoporosis
(n = 13, 11%), depression (n = 7, 6%), and diabetes (n = 6,
5%). Half of patients received two cDMARDs (mean 2.1
[SD 0.8]) between RA diagnosis and the start of the
observation period (24months prior to enrolment). The
mean number of cDMARDs received between RA diagno-
sis and enrolment was 2.4 (SD 0.9).
Patient-reported outcome measures
Of 114 patients included in the study, 102 (89%) com-
pleted PRO questionnaires. The PRO results are pre-
sented in Table 2. All PROs show some level of
impairment in patients with moderate RA. The mean
EQ-5D-5L crosswalk index value for patients with mod-
erate RA was 0.62 (SD 0.24), lower than the population
norm (0.82, age 55–64 in England). The mean EQ-5D-
5L VAS score in this cohort was 62.2 (SD 20.0).
Most patients reported some level of impairment (i.e.
levels 2–5) for the EQ-5D domains of pain/discomfort
(98/102, 96% of patients), usual activities (73/102, 72%),
and mobility (61%; Fig. 2). Patients reported a mean pain
VAS score of 37.7 (SD 24.0) indicating moderate pain,
and mean HAQ-DI of 1.1 (SD 0.8) showing moderate
disability. Thirty-four changes in employment due to RA
were recorded since diagnosis in 54 (59%) patients who
were employed prior to RA diagnosis; 14 stopped work
and 11 reduced their working hours. Fourty-1 % (n = 22)
of patients reported no change in employment status
due to moderate RA. In those who were still employed
and completed the WPAI (n = 26), a mean 29% (SD
26%) reduction in work productivity was recorded. The
median FACIT-F overall score for patients with moder-
ate RA was 97.0 (IQR 83.6–104.6). The violin plots pre-
sented in Fig. 3 show that patients experienced
significant fatigue as a result of their RA (median 17.2
[IQR 11.0–28.8]). The median duration of MJS was 1.0
(IQR 0.3–2.0) hour, and the median MJS severity score
was 4.0 (IQR 2.0–6.0) indicating moderate stiffness.
Activities of daily living that patients most commonly re-
quired assistance with included gripping or opening
Fig. 1 Flow chart of patient selection
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things (64%), housework (47%), reaching for/picking up
things (45%), and shopping (43%).
Caregiver-reported outcome measures
Thirty-eight caregivers completed questionnaires (see
Table e1 in Additional file 1); mean age was 65.1 (SD
12.7) years and 65% (24/67) were male. The mean EQ-
5D-5L crosswalk index value for caregivers was 0.80 (SD
0.16), and mean EQ-5D-5L VAS score was 76.3 (SD
16.9). Most caregivers reported no problems for most of
the EQ-5D domains, including self-care (n = 36, 95%),
usual activities (n = 28, 74%), anxiety/depression (n = 26,
68%), and mobility (n = 26, 68%); however, 71% (n = 27)
reported slight or moderate pain or discomfort. Median
scores for caregivers across the WPAI domains were 0%
except for activity impairment which was 10% (IQR 0–
45%). Mean CRA subscale scores for finance (1.9 [SD
0.9]), health (1.7 [SD 0.8]), schedule disruption (2.3 [SD
1.0]), and family support (1.9 [SD 0.8]) indicate mild to
moderate negative impact on the caregiver. Fifty-six per-
cent (20/36) of caregivers provided > 7 h of support care
per week to the patient with RA, while 8% (3/36) pro-
vided > 35 h of care per week. Sixty-one percent of care-
givers (11/18) reported no change in their employment
status as a result of caring for the person with moderate
RA; however, five caregivers (28%) took paid and/or un-
paid leave and three (17%) stopped work or reduced
working hours.
Healthcare resource utilisation in 12months prior to
enrolment
Patients had a mean of 5.5 (SD 4.1) outpatient attendances
in the 12months prior to enrolment (Table 3); routine re-
view was the most common reason (301/627, 48%). The
healthcare professionals most commonly seen during out-
patient attendances in the 12months prior to enrolment
were phlebotomists (313/822, 38% of attendances), spe-
cialist nurses (182/822, 22%), and consultants (144/822,
18%). The mean number of diagnostic and monitoring
tests per patient was 13 (SD 13.3). There was only one in-
patient admission and no A&E attendances.
All patients received treatment with ≥1 cDMARD in
the 12 months prior to enrolment (mean 1.8 [SD 0.7]).
Fifty-four percent (61/114) of patients had no new
cDMARD initiated or dose change to ongoing cDMARD
in the 12months prior to enrolment. Patients had a
mean of 3.0 (SD 1.3) RA treatments (including
cDMARDs and other RA treatments) in the 12months
prior to enrolment. Ongoing treatments at enrolment in-
cluded cDMARDS such as methotrexate (n = 93, 82%),
hydroxychloroquine (n = 48, 42%), sulfasalazine (n = 31,
27%), leflunomide (n = 9, 8%), and azathioprine (n = 1,
1%), and other RA treatments including corticosteroids
(n = 7, 6%), other painkillers (n = 43, 38%), nonsteroidal
Table 1 Patient demographics and clinical characteristics (n =
114)
Demographic/clinical variables Number of patients
(%)a
Age (years) at diagnosis N = 108b
Mean (SD) 55.5 (13.9)
Gender
Female 85 (75)
DAS28 score closest to enrolment
< 2.6 0 (0)
2.6 < 3.2 0 (0)
3.2≤ 5.1 114 (100)
> 5.1 0 (0)
Mean (SD) 3.8 (0.5)






Median (IQR) 1.0 (1.0–3.0)






Median (IQR) 3.0 (2.0–5.0)






≥ 5 3 (3)
Median (IQR) 2.0 (1.0–2.0)
Number of cDMARDs received between RA diagnosis and start
of observation periodc





≥ 5 1 (1)
Mean (SD) 2.1 (0.8)
cDMARDs Conventional disease-modifying anti-rheumatic drugs, DAS Disease
activity score, IQR Interquartile range, RA Rheumatoid arthritis, SD
Standard deviation
aResults reported as n (%) unless otherwise indicated (e.g. mean, median)
bSix patients did not have a date of diagnosis recorded
cStart of observation period is 24 months prior to enrolment
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anti-inflammatory drugs (NSAIDs; n = 25, 22%), and
other (n = 5, 4%). The total median HCRU cost per pa-
tient was £567 (IQR £361–1031) during the 12-month
observation period. The highest median HCRU cost per
patient in the 12-month period prior to enrolment was
for outpatient attendances, costing £336 (IQR £243–
516) per patient (see Table e2 in Additional file 2).
Discussion
This real-world study examines the burden of moderate
RA in UK patients who are not eligible for advanced
therapies based on current access restrictions. Our re-
sults suggest that moderate RA in these patients has a
considerable impact on the utilisation of healthcare re-
sources and on patients’ and caregivers’ lives, which ap-
proaches that of patients with severely active RA.
Patient demographics were generally consistent with
those reported from the national, prospective, ongoing
British Society of Rheumatology Biologics Register for
Rheumatoid Arthritis; however, patients were slightly
younger than patients with RA registered in the UK Bio-
bank cohort [37, 38]. The median disease duration was
shorter than that of other UK studies reported in the lit-
erature [37, 39]. Comorbidities were similar to those re-
ported for patients with RA by the UK Biobank (e.g.
depression, diabetes); however, a higher proportion of pa-
tients had cardiovascular comorbidities in this study [38].
This likely reflects a patient sampling and data recoding
issue; however, cardiovascular risk is an important comor-
bidity in RA and has historically been attributed to disease
activity thus this is an area that warrants further study.
Whilst patients were not excluded from the study if
they had a DAS28 score indicating mild RA in the 12
months prior to enrolment, only 10 and 17% of DAS28
scores in the last 12 months were in remission or LDA,
respectively. The remaining 73% were moderate which
implies most patients had persistently moderate disease.
Patient- and caregiver-reported outcomes
Patients with moderate RA showed some level of impair-
ment in all PRO measures used in our study. Despite
Table 2 Patient-reported outcomes among patients diagnosed
with moderate RA (n = 102)
Patient-reported outcome measure Value
EQ-5D-5L, mean (SD)
EQ-5D crosswalk index value (n = 102) 0.62 (0.24)
VAS (n = 99) 62.2 (20.0)
WPAI, median (IQR)
Absenteeisma (n = 26) 0 (0–1)
Presenteeismb (n = 28) 20 (10–40)
Work productivity lossc (n = 26) 20 (10–48)
Activity impairment (n = 91) 40 (10–60)
Pain VAS (n = 99), mean (SD) 37.7 (24.0)
FACIT-F, median (IQR)
Overall (0–160; n = 94) 97 (83.6–104.6)
Physical well-being sub-score (0–28; n = 102) 21 (14.0–24.0)
Social/family well-being sub-score (0–28; n = 95) 23 (17.5–26.6)
Emotional well-being sub-score (0–24; n = 99) 18 (14.0–20.0)
Functional well-being sub-score (0–28; n = 100) 18 (12.0–23.0)
Fatigue subscale (0–52; n = 98) 17.2 (11.0–28.8)
Morning Joint Stiffness
Duration (hours; n = 94), median (IQR) 1.0 (0.3–2.0)
Severity (n = 101), median (IQR) 4.0 (2.0–6.0)
HAQ-DI, mean (SD) 1.1 (0.8)
Activities of daily living requiring support, n (%)
Gripping/opening things 65 (64)
Housework 48 (47)
Reaching for/picking up things 46 (45)
Shopping 44 (43)
Gardening 39 (38)
Cooking and preparing food 37 (36)
Attending healthcare appointments 37 (36)
Getting up from sitting or lying down 27 (26)
Dressing/grooming 23 (23)
Moving around outdoors 22 (22)
Taking medication 15 (15)
Moving around indoors, including stairs 14 (14)
Washing and hygiene 13 (13)
Leisure activities 13 (13)
Eating/drinking 8 (8)
Other 5 (5)
Employment status change (in patients who were employed prior to RA
diagnosis, n = 54) because of moderate RAd, n (%)
Stopped work 14 (26)
Reduced work hours 11 (20)
Took paid leave 2 (4)
Took unpaid leave 1 (2)
Other 6 (11)
Table 2 Patient-reported outcomes among patients diagnosed
with moderate RA (n = 102) (Continued)
Patient-reported outcome measure Value
No changes in employment status because of RAe 22 (41)
EQ-5D-5L EuroQoL- 5 dimension, FACIT-F Functional Assessment of Chronic
Illness Therapy - fatigue scale, HAQ-DI Health Assessment Questionnaire
Disability Index, IQR Interquartile range, RA Rheumatoid arthritis, SD Standard
deviation, VAS Visual analogue scale, WPAI Work Productivity and
Activity Impairment
a% work time missed
b% work time lost due to reduced effectiveness
cAbsenteeism + presenteeism
dNot mutually exclusive
dIncludes patients who were already retired
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treatment, many patients reported significantly impaired
HRQoL, as demonstrated by the EQ-5D-5L mean index
score of 0.62 compared to an England population norm
of 0.82. This is consistent with a previous report by
Pavelka et al. which reported a mean EQ-5D-5L index
score of 0.59 despite patients having on average more se-
vere disease than that seen in our study (mean DAS28
score 4.4 versus 3.8 in our study) [40]. The EQ-5D-5L
we report is higher than that reported in a Swedish (EQ-
5D-5L mean index score 0.34; mean DAS28 5.0) and a
wider European study (EQ-5D-5L mean index score
0.53) [41, 42]. The HRQoL is affected by the level of se-
verity as measured by DAS28 and other factors including
culture, socioeconomic status, perception, healthcare
system, and social structure. The VAS of 62.2 was con-
sistent with previous reports in 54 patients with RA
(46% with high and 41% with moderate disease activity)
[43]. Pain (96%) and inability to do usual activities (73%)
were key drivers for HRQoL impairment according to
EQ-5D in our study.
The FACIT fatigue subscale score for this study (17.2)
was lower than those reported by Pavelka et al., Smolen
et al. (mean DAS28 4.4), and Žagar et al. (32.4, 33.7, and
28.7, respectively) indicating that patients in this study
experienced significantly more fatigue as a result of their
RA despite a lower mean DAS28 [40, 43, 44]. Corticoste-
roids are a driver of fatigue; however, only 6% of patients
had ongoing treatment with corticosteroids at enrol-
ment. Hence, it is unlikely the burden of fatigue ob-
served in this study was due to steroid treatment. The
presence of comorbidities or the contribution of undiag-
nosed low mood are alternative explanations. The possi-
bility that this is a chance finding due to small sample
size cannot be ruled out.
Patients in our study experienced moderate disability
(mean HAQ-DI score 1.1). Mean HAQ-DIs of 1.2, 1.1, 1.2,
and 1.0 were recorded in other studies with higher mean
DAS28 scores of 4.4, 4.4, 5.0, and 4.5, respectively [23, 40,
44, 45]. The median duration (1.0 h) and moderate
severity of morning joint stiffness in our patients was also
comparable to other studies where the mean DAS28 was
slightly higher at 4.5 and 4.4 [23, 44]. Together, these data
suggest that the burden of disease in this cohort ap-
proaches that of patients with severely active RA. This
study demonstrates the burden of disease and exposes an
opportunity to improve lives. Recognising the patient im-
pacts of moderate disease allows clinicians to appreciate
the potential benefits that could be achieved if remission
was attained [18]. A study which assessed the impact of
biologics on RA disease activity and quality of life showed
that Kuwaitis who had easy access to biologics reported
significantly better treatment outcomes including lower
numbers of swollen joints and DAS28 scores compared to
non-Kuwaitis [46].
Total work productivity loss (mean 29% in this study
versus 33.5 and 43.2%) and activity impairment (mean
37% versus 48.1 and 56.2%) were lower than that re-
ported in other studies which included patients with
more severe disease [42, 47]. However, work productivity
loss was higher than that reported in a Latin American
study (mean 8.6% across Argentina, Brazil, Colombia,
and Mexico) despite most patients classified as having
high severity [48]. A European cross-sectional study of
the impact of disease severity and duration on cost, early
retirement, and ability to work in RA reported greater
levels of work impairment with increased disease activity
and pain level [5]. An assessment of the association be-
tween work impairment and other variables would be in-
teresting but this was beyond the scope of our study.
We show that moderate RA still has a significant impact
on patients’ ability to work with WPAI values compar-
able to other chronic illnesses, such as chronic obstruct-
ive pulmonary disease, asthma and irritable bowel
syndrome [49]. Almost half of patients in our cohort had
changes in employment due to their RA and in those
who remained employed and completed the WPAI, a
mean 29% reduction in work productivity was recorded.
This has high cost implications as it has recently been
Fig. 2 Patients’ quality of life (EQ-5D-5L) by domain and level. *Level 1 = no problems; level 2 = slight problems; level 3 =moderate problem; level
4 = severe problems; level 5 = extreme problems
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suggested that the greatest impact on costs for patients
with RA is reduced performance while working (at-work
productivity loss) [50].
Data from this study also show a significant impact on
caregivers looking after patients with moderate RA. Over
50% of caregivers provided > 7 h of support care per
week to the patient with RA, mean CRA subscale scores
indicate mild to moderate negative impact on the care-
giver, and 16 and 11% took paid and/or unpaid leave or
reduced working hours, respectively. There are little data
available on caregiver burden in RA. Here we show that
the burden of moderate RA extends beyond the patient.
Healthcare resource utilisation
Data on HCRU for patients with moderate RA are sparse
within the literature. Existing data show similar levels of
day case admissions (mean 0.2 in the literature versus
0.1 in the 12months prior to enrolment in our study)
and cDMARD utilisation (mean 1.43 in the literature
versus 1.8 in our study) [39]. It should be noted how-
ever, that in the period reviewed in this study the ‘treat-
to-target’ principle may not have been fully imple-
mented. The distribution of cDMARDs is consistent
with previous UK data [39]. The median disease dur-
ation was 5.1 years at current cDMARD initiation, and
over half of patients had not had a dose change to their
cDMARD therapy in the last year, despite having
moderate disease. This combined with the fact that pa-
tients received a mean of 2.4 cDMARDs between RA
diagnosis and enrolment may imply a lack of additional
effective options for these patients. Relatively frequent
outpatient attendances and diagnostic/monitoring tests
in the 12-month period prior to enrolment, and the fact
that all patients were receiving treatment with
cDMARDs in this period suggests that the management
of moderate RA places a significant burden on the NHS.
Strengths and limitations
This study represents one of the most comprehensive at-
tempts to measure burden of disease in a population of
UK patients with moderate RA. We used a range of vali-
dated PRO measures and also considered caregiver and
health service perspectives to give an all-round better
picture of the burden of moderate RA in the UK. Some
limitations however also need consideration. First, the
sample may not be representative. The consent rate was
63%, and the characteristics of the patients who con-
sented may not be representative of the wider popula-
tion of patients with moderate RA. Patients included in
this study were under the care of physicians and study
sites that were willing to participate and therefore these
centres may not be representative of current wider UK
secondary care clinical practice. Another possible limita-
tion is that the interpretation of data collected
Fig. 3 Violin plots showing FACIT-F subscale scores. The median, interquartile range, range, and kernel density are displayed, and the blue numbers in
parentheses represent the number of responses
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retrospectively is dependent on the completeness and
quality of the medical records and the reliability of data
abstraction. We employed SDV in this study to identify
and correct abstraction errors. Furthermore, patient-
reported data are subject to recall bias; however, this
likely had little impact on the results as only short recall
was required. Finally, due to only 6% of patients having
ongoing treatment with corticosteroids at enrolment, the
results may not be generalisable to other non-UK co-
horts where steroid use is more prevalent.
Conclusions
In conclusion, we show that moderate RA requires frequent
hospital visits for clinic appointments and has a considerable
impact on the lives of patients (and their caregivers) who are
not eligible for advanced therapies based on current access
restrictions. The impact (for fatigue, disability, and pain/dis-
comfort) is comparable to that seen in patients on the more
severe end of the RA disease spectrum. This suggests that
there is substantial opportunity for patients within this dis-
ease severity spectrum. The information presented here will
aid decision making around the cost benefit of different
therapeutic strategies for this often overlooked RA
subpopulation.
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